Earnings call transcript: BioMarin Q1 2026 results beat forecasts, stock dips

BioMarin beat Q1 2026 expectations with EPS of $0.76 versus $0.74 consensus and revenue of $766 million versus $755.94 million, though shares fell 1.52% after hours to $53.24. Management raised full-year 2026 revenue guidance to $3.825 billion-$3.925 billion and EPS to $4.85-$5.05 after closing the Amicus acquisition, which is expected to be slightly dilutive in 2026 but accretive from 2027. The update also highlighted strong Voxzogo and enzyme therapy demand, with more than 20% year-over-year growth in treated children for Voxzogo.

Analysis

The market is treating this as a classic “beat-and-fade,” but the more important signal is that BioMarin is transitioning from a single-asset growth story to a portfolio compounding story. The Amicus assets materially reduce dependence on Voxzogo timing and enzyme-therapy cadence, which should compress revenue volatility and make the multiple less hostage to quarterly shipping noise. That said, the market is likely discounting execution risk because the near-term earnings bridge is now unusually back-half loaded; any slip in integration or uptake would hit 2026 numbers disproportionately.

Competitive dynamics look better than the headline suggests. BioMarin’s real advantage is not just product breadth, but its ability to industrialize diagnosis and switching in ultra-rare diseases; that creates a higher barrier than product-only competitors can easily replicate. The second-order effect is that smaller niche players in Fabry/Pompe and skeletal conditions may face a tougher commercial environment if BioMarin uses its field force and evidence-generation machine to accelerate patient finding faster than rivals can defend share.

The underappreciated risk is that investors may be over-indexing on the accretion story while underestimating the cost of integration and the need to prove incremental uptake, not just bought revenue. The high-multiple profile means the stock likely needs either a clean Q2 integration update or a strong pipeline readout to rerate; otherwise, it can drift lower as the market waits for 2027 accretion to become tangible. Near term, the most likely reversal catalyst is evidence that Palynziq adolescent penetration and Voxzogo under-2 starts are translating into durable revenue inflection rather than merely front-loaded enrollment.

Contrarian view: the selloff may be too cautious if management delivers even a modestly better-than-feared Q2 on synergies and long-term peak-sales framing. The setup favors patience because the upside is asymmetrically driven by three catalysts across different time horizons: integration clarity in weeks, pipeline data in months, and accretion in years. In other words, this is not a “today” earnings trade so much as a multi-stage re-rating candidate that needs one more proof point to clear the current valuation overhang.

Key Decisions for Investors

• Buy BMRN on weakness into the next 2-4 weeks with a tight thesis: if Q2 integration commentary confirms even modest synergy capture, the stock can re-rate 8-12% from current levels; stop if management punts on peak-sales detail or synergy timing.
• Pair trade: long BMRN / short a basket of smaller rare-disease commercial names over the next 1-2 quarters; BioMarin’s scale in diagnosis, reimbursement, and evidence generation should outcompete smaller asset-light peers if launch execution stays clean.
• Buy BMRN Jan-2027 calls or call spreads to express the 2027 accretion thesis; the market is pricing too much 2026 dilution and too little optionality on Galafold/Pombiliti penetration and BMN-333 pipeline value.
• Short-dated caution hedge: if long BMRN, partially fund with covered calls through the next catalyst window; the stock is likely range-bound until either Q2 integration metrics or pipeline data de-risks the story.